Shares of OraSure Technologies (NASDAQ:OSUR) were riding high in July after the company gained FDA approval to market its over-the-counter HIV testing kit. The stock's value has eroded since then, however, and is now at a 52-week low after its Q4 earnings results sent shares down more than 13% in intraday trading. In this video, health care analyst Max Macaluso reviews OraSure's 2012 results and what investors should watch in upcoming quarters.

Editor's note: At 1:08, Max meant to say that analyst estimates for Q1 were more than $23 million, according to Yahoo! Finance -- not $37 million. The Fool regrets the error.